Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties

被引:753
作者
Wager, Travis T. [1 ]
Hou, Xinjun [1 ]
Verhoest, Patrick R. [1 ]
Villalobos, Anabella [1 ]
机构
[1] Pfizer PharmaTherapeut Res & Dev, Neurosci Med Chem, Groton, CT 06340 USA
关键词
Multiparameter optimization (MPO); central nervous system (CNS); CNS MPO; CNS drugs; CNS candidates; lipophilicity; topological polar surface area; polarity; molecular weight; hydrogen bond donor; most basic pK(a); high-throughput screening; passive permeability; Madin-Darby canine kidney; P-glycoprotein; human liver microsome stability; Unbound intrinsic clearance; drug-drug interactions; dofetilide binding; transformed human liver epithelial cells; cellular toxicity; Harrington optimization; desirability score; multivariant optimization; DISCOVERY; PROLONGATION; PREDICTION; BINDING;
D O I
10.1021/cn100008c
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The interplay among commonly used physicochemical properties in drug design was examined and utilized to create a prospective design tool focused on the alignment of key druglike attributes. Using a set of six physicochemical parameters ((a) lipophilicity, calculated partition coefficient (ClogP); (b) calculated distribution coefficient at pH = 7.4 (ClogD); (c) molecular weight (MW); (d) topological polar surface area (TPSA); (e) number of hydrogen bond donors (HBD); (f) most basic center (pK(a))), a druglikeness central nervous system multiparameter optimization (CNS MPO) algorithm was built and applied to a set of marketed CNS drugs (N = 119) and Pfizer CNS candidates (N = 108), as well as to a large diversity set of Pfizer proprietary compounds (N = II 303). The novel CNS MPO algorithm showed that 74% of marketed CNS drugs displayed a high CNS MPO score (MPO desirability score >= 4, using a scale of 0-6), in comparison to 60% of the Pfizer CNS candidates. This analysis suggests that this algorithm could potentially be used to identify compounds with a higher probability of successfully testing hypotheses in the clinic. In addition, a relationship between an increasing CNS MPO score and alignment of key in vitro attributes of drug discovery (favorable permeability, P-glycoprotein (P-gp) efflux, metabolic stability, and safety) was seen in the marketed CNS drug set, the Pfizer candidate set, and the Pfizer proprietary diversity set. The CNS MPO scoring function offers advantages over hard cutoffs or utilization of single parameters to optimize structure activity relationships (SAR) by expanding medicinal chemistry design space through a holistic assessment approach. Based on six physicochemical properties commonly used by medicinal chemists, the CNS MPO function may be used prospectively at the design stage to accelerate the identification of compounds with increased probability of success.
引用
收藏
页码:435 / 449
页数:15
相关论文
共 25 条
[1]   Ligand efficiency indices for effective drug discovery [J].
Abad-Zapatero, Cele .
EXPERT OPINION ON DRUG DISCOVERY, 2007, 2 (04) :469-488
[2]   A fast exchange algorithm for designing focused libraries in lead optimization [J].
de Tilleghem, CL ;
Beck, B ;
Boulanger, B ;
Govaerts, B .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2005, 45 (03) :758-767
[3]  
Deacon Matt, 2007, Journal of Pharmacological and Toxicological Methods, V55, P238, DOI 10.1016/j.vascn.2006.09.003
[4]   Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties [J].
Ertl, P ;
Rohde, B ;
Selzer, P .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (20) :3714-3717
[5]   In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system [J].
Feng, Bo ;
Mills, Jessica B. ;
Davidson, Ralph E. ;
Mireles, Rouchelle J. ;
Janiszewski, John S. ;
Troutman, Matthew D. ;
de Morais, Sonia M. .
DRUG METABOLISM AND DISPOSITION, 2008, 36 (02) :268-275
[6]   The impact of drug-induced qt interval prolongation on drug discovery and development [J].
Fermini, B ;
Fossa, AA .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (06) :439-447
[7]   In silico modeling of nonspecific binding to human liver microsomes [J].
Gao, Hua ;
Yao, Lili ;
Mathieu, Heather W. ;
Zhang, Ying ;
Maurer, Tristan S. ;
Troutman, Matthew D. ;
Scott, Dennis O. ;
Ruggeri, Roger B. ;
Lin, Jing .
DRUG METABOLISM AND DISPOSITION, 2008, 36 (10) :2130-2135
[8]   MOLECULAR RECOGNITION OF THE INHIBITOR AG-1343 BY HIV-1 PROTEASE - CONFORMATIONALLY FLEXIBLE DOCKING BY EVOLUTIONARY PROGRAMMING [J].
GEHLHAAR, DK ;
VERKHIVKER, GM ;
REJTO, PA ;
SHERMAN, CJ ;
FOGEL, DB ;
FOGEL, LJ ;
FREER, ST .
CHEMISTRY & BIOLOGY, 1995, 2 (05) :317-324
[9]  
Harrington E.C., 1965, Industrial Quality Control, V21, P494, DOI DOI 10.1128/AM.13.3.494-495.1965
[10]   Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches [J].
Hosea, Natilie A. ;
Collard, Wendy T. ;
Cole, Susan ;
Maurer, Tristan S. ;
Fang, Rick X. ;
Jones, Hannah ;
Kakar, Shefali M. ;
Nakai, Yasuhiro ;
Smith, Bill J. ;
Webster, Rob ;
Beaumont, Kevin .
JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (05) :513-533